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Graphical abstract 
 
 
Highlights 
 Targeted loop engineering of a GH29 fucosidase for improved transfucosylation  
 3-fold yield increase in the enzyme’s conversion efficacy on the fucosyl donor  
 Enzymatic synthesis of fucosylated human milk oligosaccharides LNFP II and LNFP III  
 
Abstract 
The α-1,3/4-L-fucosidases (EC 3.2.1.111; GH29) BbAfcB from Bifidobacterium bifidum and CpAfc2 
from Clostridium perfringens can catalyse formation of the human milk oligosaccharide (HMO) lacto-
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N-fucopentaose II (LNFP II) through regioselective transfucosylation of lacto-N-tetraose (LNT) with 3-
fucosyllactose (3FL) as donor substrate. The current work exploits structural differences between the 
two enzymes with the aim of engineering BbAfcB into a more efficient transfucosidase and 
approaches an understanding of structure-function relations of hydrolytic activity vs. 
transfucosylation activity in GH29. Replacement of a 23 amino acids long α-helical loop close to the 
active site of BbAfcB with the corresponding 17-amino acid α-helical loop of CpAfc2 resulted in 
almost complete abolishment of the hydrolytic activity on 3FL (6000 times lower hydrolytic activity 
than WT BbAfcB), while the transfucosylation activity was lowered only one order of magnitude. In 
turn, the loop engineering resulted in an α-1,3/4-L-fucosidase with transfucosylation activity reaching 
molar yields of LNFP II of 39±2% on 3FL and negligible product hydrolysis. This was almost 3 times 
higher than the yield obtained with WT BbAfcB (14±0.3%) and comparable to that obtained with 
CpAfc2 (50±8%). The obtained transfucosylation activity may expand the options for HMO 
production: mixtures of 3FL and LNT could be enriched with LNFP II, while mixtures of 3FL and lacto-
N-neotetraose (LNnT) could be enriched with LNFP III.  
Abbreviations 
 
2’FL: 2’-fucosyllactose; 3FL: 3-fucosyllactose; A:D: acceptor-to-donor ratio; BbAfcB: α-1,3/4-L-
fucosidase from Bifidobacterium bifidum; BiAfcB: α-1,3/4-L-fucosidase from Bifidobacterium longum 
subsp. infantis; CpAfc2: α-1,3/4-L-fucosidase from Clostridium perfringens; Fuc: fucose; GH: glycoside 
hydrolase; Gal: galactose; Glc: glucose; GlcNAc: N-acetylglucosamine; HMO: human milk 
oligosaccharide; LNT: lacto-N-tetraose; LNnT: lacto-N-neotetraose; LNFP: lacto-N-fucopentaose; Sia: 
sialic acid; WT: wild type.  
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Introduction 
 
Human milk oligosaccharides (HMOs) are soluble complex glycans which are present in human milk 
at concentrations of 5-15 g/L, often exceeding the concentration of protein thus being the third most 
abundant component in human milk. In the human colostrum, concentrations are even higher [1]. In 
contrast, HMOs are virtually absent from bovine milk, which is the basis of infant formula. Approx. 
1% of the HMOs are adsorbed, while the majority is either metabolized by the gut microbiota of the 
infant or excreted in the faeces [2, 3]. HMOs function as prebiotics and antimicrobial agents in the 
gut of breastfed infants, and they further protect the infant against pathogens by functioning as 
soluble decoy receptors for pathogen adhesion as well as through a number of immunomodulating 
effects. HMOs may also be involved in infant brain development [1]. No single HMO has all these 
effects at once, suggesting why as many as 200 different HMO structures have been identified in 
human milk [4, 5]. 
Five monosaccharides, i.e. galactose (Gal), glucose (Glc), N-acetylglucosamine (GlcNAc), 
fucose (Fuc), and sialic acid (Sia) derivative N-acetyl-neuraminic acid, form the HMO building blocks. 
All HMO molecules have lactose (Gal-β1,4-Glc) at the reducing end can be elongated in β1,3- or β1,6-
linkages by two different disaccharide moieties, namely Gal-β1,3-GlcNAc (type 1) or Gal-β1,4-GlcNAc 
(type 2). The HMO backbone can be further modified with Sia and/or Fuc substitutions [1, 5]. Among 
them, the fucosylated species are the most abundant – at least in breastmilk of approx. 80% of the 
population since the degree and type of HMO fucosylation are linked to the secretor and Lewis blood 
status group of the mother [6].  
 Several routes to production of HMOs in vitro exist, one of them being the use of 
glycosidases catalysing transglycosylation [7, 8, 9]. Advantages of glycosidases include easy 
expression, robustness, and the option of using inexpensive naturally occurring donor substrates. 
Indeed, the α-1,3/4-L-fucosidase BiAfcB from Bifidobacterium longum subsp. infantis (EC 3.2.1.111) 
was recently shown to catalyse transfucosylation of the HMO core structure lacto-N-tetraose (LNT) 
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with another HMO, namely 3-fucosyllactose (3FL), as fucosyl donor leading to formation of lacto-N-
fucopentaose II (LNFP II) [10] (Figure 1). For this WT enzyme, transfucosylation yields on 3FL ranged 
from 6% to 12% depending on the substrate concentration, but through elaborate engineering of 
BiAfcB mutants transfucosylation yields on 3FL of up to 60% were achieved [10, 11]. We recently 
studied two WT α-L-1,3/4-fucosidases (EC 3.2.1.111) – BbAfcB from Bifidobacterium bifidum and 
CpAfc2 from Clostridium perfringens: In terms of their transfucosylation potential CpAfc2 was 
superior to the BbAfcB producing molar transfucosylation yields of up to 39% (on the donor 3FL) in 
production of LNFP II [12]. These α-L-fucosidases belong to the glycoside hydrolase family 29 
subfamily B (GH29B) which comprises retaining α-L-fucosidases with high specificity for branched α-
1,3/4-fucosylations [13]. In turn, GH29B α-1,3/4-L-fucosidases have also been shown to possess high 
regioselectivity in transfucosylation [10, 12].  
When comparing the transfucosylation and hydrolytic activities of BbAfcB and CpAfc2 it was 
evident that CpAfc2 had markedly higher transfucosylation activity than BbAfcB using 3FL and LNT for 
formation of LNFP II, and that BbAfcB in turn had significantly higher hydrolytic activity on 3FL than 
CpAfc2 [12]. Unfortunately, C. perfringens is a potential pathogen, so the use of an enzyme derived 
from this organisms for production of HMOs for infant formulae may be controversial. In contrast, B. 
bifidum is considered a beneficial probiotic microbe. Consequently, the current work set out to 
exploit any structural differences between the two GH29B α-1,3/4-L-fucosidases with the aim of 
engineering of BbAfcB for improving its transfucosylation activity and/or reducing its hydrolytic 
activity. Comparison of homology models of BbAfcB and CpAfc2 with the crystal structure of the well-
studied BiAfcB, reveal that BbAfcB and CpAfc2 appear similar in terms of active site structure and 
substrate-interacting residues. However, the models of the active site region suggest that an α-
helical loop on the side of the active site constitutes a major difference between BbAfcB and CpAfc2. 
Since the transsialylation yield of a sialidase from Trypanosoma rangeli could be significantly 
improved by replacing a loop near the active site with the corresponding loop of a native 
transsialidase from T. cruzi [14], a similar approach was pursued here: The identified α-helical loop in 
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BbAfcB was replaced with that of CpAfc2, hypothesizing that the shape of the loop in CpAfc2 provide 
better shielding of the active site from the aqueous environment and that this feature could be 
transferred to BbAfcB by loop engineering.  
  
Materials & Methods 
 
Chemicals 
The fucosylated oligosaccharides 3-fucosyllactose (3FL), lacto-N-tetraose (LNT), lacto-N-neotetraose 
(LNnT), and lacto-N-fucopentaose V (LNFP V) were purchased from Elicityl Oligotech (Crolles, France). 
All other chemicals were purchased from Sigma-Aldrich (Steinheim, Germany).  
 
Homology modelling  
Structure homology models were prepared using the Homology Modeling function of YASARA 
Structure, version 16.9.23 (YASARA Biosciences GmbH, Vienna, Austria) [15].The program identified 
automatically the following template structures in structural databases: 4ZRX, 3UES, 3MO4, 2BER, 
2X0Y for BbAfcB  and 4ZRX, 5K9H, 3EYP, 3RB5, 2OZN for CpAfc2. For each of the templates up to 5 
homology models were prepared by the program, which afterwards were automatically ranked. 
Based on the ranking a hybrid model was prepared by the program, which finally was equilibrated by 
molecular dynamics simulation using the YASARA macro md_refine without changes [16]. The refined 
models with the lowest energy were quality checked using QMEAN4 [17] and subsequently used for 
comparison with the BiAfcB structure 3UET. All figures showing 3D structures were prepared using 
PyMol (The PyMOL Molecular Graphics System, Version 1.1 Schrödinger, LLC). Sequence alignments 
were made with MUSCLE 3.8 [18].   
 
Cloning, expression and purification of α-L-fucosidases 
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The sequence of α-L-1,3/4-fucosidase BbAfcB from Bifidobacterium bifidum JCM 1254 (GenBank 
BAH80310.1; EC 3.2.1.111) was slightly truncated and codon-optimized for expression in Escherichia 
coli previously [12]. The resulting pET22b+/bbafcb plasmid was used as a template for deletion of the 
encoded loop 759-AAYNDGVDKVSLKPGQMAPDGKL-781 and introduction of the new loop 
DIEKMKERENPTYLNNG originating from α-L-1,3/4-fucosidase CpAfc2 from Clostridium perfringens 
ATCC 13124 (GenBank ABG83106.1; EC 3.2.1.111) [12, 19] by PCR using the forward primer 5’-
AACCCGACCTATCTGAACAACGGCGGCAGCATGAGCAGCGTGCTGAGCGAG-3’ and the reverse primer 5’-
TTCACGTTCTTTCATTTTTTCGATATCTTGCGGGCTCCATTCGGTCTGACGCGCC-3’ where underlined 
nucleotides correspond to the new loop sequence (Table A.1; Table A.2). The plasmid template was 
removed by DpnI digestion. After purification using Illustra GFX PCR DNA and Gel Band Purification 
kit (GE Healthcare, Chicago, IL, USA), the PCR product was phosphorylated using T4 polynucleotide 
kinase (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C during 1 hour and ligated overnight at 
16°C using T4 DNA ligase (Thermo Fisher Scientific, Waltham, MA, USA). The ligated PCR product was 
then transformed into competent E. coli DH5α cells, prepared with the Mix & Go E. coli 
Transformation kit (Zymo Research, Irvine, CA, USA). Plasmid was extracted using QIAprep Spin 
Miniprep kit (Qiagen, Hilden, Germany) and checked by sequencing (Macrogen Europe, Amsterdam, 
the Netherlands). 
Expression and purification of BbAfcB, BbAfcBmut, and CpAfc2 were carried out in E. coli BL21 
(DE3) as described previously [12]. Protein purity was confirmed by SDS-PAGE and protein 
concentration was determined with the BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, 
MA, USA) using bovine serum albumin (BSA) standards.  
 
Hydrolytic activity and HPAEC-PAD analysis 
Hydrolytic activity was determined for BbAfcB, BbAfcBmut, and CpAfc2 using 0.1 mM 3FL in 50 mM 
buffer (acetate buffer pH 5.5 for BbAfcB and BbAfcBmut according to the pH optimum of BbAfcB 
established by Ashida et al. [20], and phosphate buffer pH 7.0 for CpAfc2 according to the pH 
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optimum for CpAfc2 [19]) and enzyme concentrations between 0.005 µM and 5 µM. Negative 
controls without enzyme were included. All reactions took place at 40°C, were monitored for up to 
20 min (180 min for BbAfcBmut), and stopped by mixing a sample 1:1 with 1 M Na2CO3. The amounts 
of substrate and hydrolysis products were quantified by high-performance anion exchange 
chromatography with pulsed amperometric detection (HPAEC-PAD). Specific hydrolytic activity was 
defined as µmol of product released per minute (U) per µmol of enzyme. 
 Enzyme stability at 40°C was determined by incubation of the fucosidases in the reaction 
buffer at 40°C followed by assessment of their remaining hydrolytic activity after 0, 1, 3, 5, 12, and 24 
hours of incubation as described above.  
HPAEC-PAD analysis was carried out on a Dionex ICS3000 system (Dionex Corp., Sunnyvale, 
CA, USA) using a CarboPacTM PA1 (4 mm x 250 mm) analytical column equipped with a CarboPacTM 
PA1 (4 mm x 50 mm) guard column (Dionex Corp., Sunnyvale, CA, USA) and a flow rate of 1 mL/min 
at 25°C. The eluent system comprised MilliQ water (A), 500 mM NaOH (B), and 500 mM NaOAc with 
0.02% (w/v) NaN3 (C). After enzymatic hydrolysis, 3FL was quantified by isocratic elution at 90:10:0 
(% A:B:C) for 20 min using external standards of L-fucose, lactose, and 3FL. Strongly retained anions 
were washed from the column by elution with 10:10:80 (% A:B:C) for 5 min followed by re-
equilibration of the column at 90:10:0 (% A:B:C) for 10 min.  
 
Transfucosylation activity and LC-ESI-MS analysis 
For transfucosylation of LNT and LNnT, 3FL was used as donor substrate for reactions catalysed by 
BbAfcB, BbAfcBmut and CpAfc2. Enzyme concentration was 0.5 µM and reaction took place at 40°C for 
up to 24 hours in 100 mM buffer (acetate buffer pH 5.5 for BbAfcB and BbAfcBmut, phosphate buffer 
pH 7.0 for CpAfc2). Reactions were terminated by heating at 99°C for 15 min. For reactions with an 
acceptor-to-donor ratios (A:D) of 10, donor substrate (3FL) concentration was 10 mM and acceptor 
substrate (LNT or LNnT) concentration was 100 mM. For reactions with an A:D of 1, concentrations of 
donor and acceptor substrates were 20 mM. Additional experiments were conducted with BbAfcB 
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and BbAfcBmut at the same conditions (reaction time up to 60 min) using A:Ds of 2 (10 mM 3FL and 20 
mM LNT) and 5 (20 mM 3FL and 100 mM LNT). Transfucosylation products were identified and 
quantified by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) using an 
external LNFP V standard. Transfucosylation yields were calculated as molar yields based on the 
donor substrate 3FL, i.e. the percentage of LNFP formed compared to the initial 3FL concentration. 
Initial transfucosylation rates were calculated as mM LNFP formed per min of reaction over the time 
where the product formation curve was linear (2 min for BbAfcB, 5 min for CpAfc2, and 20-30 min for 
BbAfcBmut).  
Identification and quantification of LNFP transfucosylation products were performed by LC-
ESI-MS on an Amazon SL iontrap (Bruker Daltonics, Bremen, Germany) coupled to an UltiMate 3000 
UHPLC from Dionex (Sunnyvale, CA, USA) equipped with a porous graphitized carbon column 
(Hypercarb PGC, 150 mm × 2.1 mm, 3 µm; Thermo Fisher Scientific, Waltham, MA, USA) as described 
previously [12]. LNFP isomers LNFP II, LNFP III, and LNFP V were identified from MS2 fragmentation 
patterns [21].  
 
Statistics 
One-way ANOVA for determination of statistical significance was performed with JMP®, version 
13.0.0 (SAS Institute Inc., Cary, NC, USA). Statistical significance was established at p < 0.05.  
 
Results 
 
Homology modelling  
The homology models of BbAfcB and CpAfc2 were inspected visually and their quality was checked 
using the QMEAN4 Z-score [17]. The model for BbAfcB showed a dimeric structure, but since there 
was no significant difference in between the two monomers it was decided to continue with only one 
of them. The catalytic domains for both models showed the expected (β/α)8-barrel, though one of 
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the β-strands was not modelled as such (Figure A.1). However, aligning the models with the crystal 
structures of BiAfcB (3UET) [22] and another GH29B member, namely α-L-1,3/4-fucosidase BT2192 
from Bacteroides thetaiotaomicron (4OZO) [23], revealed that even in the crystal structure this part 
of the barrel was not a perfect β-strand; thus, this could be a natural feature of these enzymes. The 
QMEAN4 Z-scores for the full-length models of BbAfcB and CpAfc2 were -2.65 and -2.61, respectively 
(Figure A.2). Deleting the C-terminal non-catalytic domain for the quality check improved the Z-score 
for BbAfcB only marginally (-2.51), but for CpAfc2 the score significantly improved to -0.62 (Figure 
A.2). The low quality score for the BbAfcB model might be caused by the long single α-helices 
present, which especially influence the packing check negatively. However, since the model of the 
catalytic domain for CpAfc2 was of good quality, the models were used to identify potential targets 
to engineer BbAfcB for improved transglycosylation performance. 
Based on inspection of the homology models and comparison to the well-studied crystal 
structure of BiAfcB, it was evident that they share all substrate-interacting residues in terms of 
position in the three-dimensional structure (Figure A.1; Figure A.3; Table A.3). However, CpAfc2 
featured an α-helical loop region on the side of the active site, approx. 13 Å from the substrate. In 
BbAfcB, the major part of this α-helical loop was further away and more disordered (Figure 2) and in 
BiAfcB it was even found to be a large disordered structure, because the structure of this loop could 
not be determined (Figure A.3). The most significant structural difference in the compared structures 
was this loop region, which was moreover found to be highly variable in the three sequences. Hence, 
the hypothesis behind the current work was that replacement of the loop sequence in BbAfcB with 
that of CpAfcB, would improve the transfucosylation ability of BbAfcB by inducing a better shielding 
of the active site from the aqueous environment. This hypothesis was further supported by 
inspection of the surface representation of the aligned models, in which it became obvious that 
especially R266 in the CpAfc2-loop might indeed shield the active site of BbAfcB, even though there is 
still room for water molecules in the active site (Figure A.4).  
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To define the exact parts of the loop in BbAfcB to be exchanged with the one from CpAfc2 
the homology models were aligned in PyMol and inspected visually. To minimize the risk of losing the 
correct foldability and also a possible dimerization of BbAfcB, the starting and end points of the loops 
to be exchanged were carefully selected based on backbone alignment. The backbones of the amino 
acid residues A759 in BbAfcB and D259 in CpAfc2 aligned well, so these residues were defined as 
starting points of the loops to be exchanged (Figure A.1). Although true backbone alignment was not 
achieved until L799 in BbAfcB and S280 in CpAfc2, detailed inspection of the modelled loop 
structures revealed that G782 of BbAfcB and E276 of CpAfc2 aligned well enough, so that these two 
positions were defined to terminate the loops to be exchanged (Figure A.1). This led to the final 
definition of the loop 759-AAYNDGVDKVSLKPGQMAPDGKL-781 in BbAfcB to be exchanged with the 
loop 259-DIEKMKERENPTYLNNG-275 from CpAfc2. 
 
Expression of recombinant α-1,3/4-L-fucosidases 
BbAfcB, BbAfcBmut loop mutant, and CpAfc2 were successfully expressed in E. coli BL21 (DE3) cells using 
LB medium. After Ni2+ affinity chromatography purification and desalting by gel filtration expression 
levels reached 24, 23, and 38 mg of purified enzyme per litre of culture, respectively. SDS-PAGE analysis 
showed that all purified extracts were satisfactorily pure (Figure A.5). 
 
Hydrolytic activity 
The hydrolytic activities of BbAfcB and CpAfc2 on 3FL were similar to the previously reported values 
[12]: 18 U/μmol enzyme for CpAfc2 and 59 U/μmol enzyme for BbAfcB. However, for BbAfcBmut the 
hydrolytic activity on 3FL was practically non-existent: 0.01 U/μmol enzyme, i.e. 6000 times lower 
than the WT enzyme (Table 1).  
 
Transfucosylation activity 
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Transfucosylation activity of BbAfcBmut, BbAfcB, and CpAfc2 was monitored for 3 hours using 3FL as 
fucosyl donor and LNT or lacto-N-neotetraose (LNnT) as acceptors. The acceptor-to-donor ratios 
(A:D) were either 10 (acceptors 100 mM LNT or LNnT and donor 10 mM 3FL) or 1 (20 mM of each 
substrate). For WT BbAfcB, maximum levels of LNFP II and LNFP III were obtained after 2 minutes of 
reaction, which was the shortest reaction time measured; after this, product levels decreased to 0 
within 2 hours of reaction (Figure 3). At A:D 10, the maximum yield of LNFP II was 14%, whereas it 
was 3.3% for LNFP III (Figure 3; Table 2). For CpAfc2, the transient maxima were reached after 30 
minutes and yields were 50% for LNFP II and 17% for LNFP III at A:D 10 (Figure 3; Table 2). For 
BbAfcBmut, no transient maxima were observed within 3 hours of reaction (Figure 3). Instead, 
maximum yields were obtained after 3 hours reaching 39% for LNFP II and 11% for LNFP III on the 3FL 
donor at A:D 10 (Figure 3, Table 2).  
Interestingly, the highest apparent initial transfucosylation rates were obtained with BbAfcB, 
being approx. 1.5 times higher than those of CpAfc2 at A:D 10 and 2-3 times higher at A:D 1 (Table 2). 
In comparison, initial transfucosylation rates were approx. one order of magnitude lower for 
BbAfcBmut compared to the two WT enzymes (Table 2).  
Additional samples were taken after 24 hours of reaction in order to investigate the degree 
of product hydrolysis. For both WT enzymes BbAfcB and CpAfc2, product degradation was complete 
after 24 hours (Table 2). However, for BbAfcBmut no significant decrease in LNFP II levels were 
observed, whereas the level of LNFP III did decrease at A:D 10 though not at A:D 1 (Table 2). After 
incubation at 40°C for 24 hours in reaction buffer, the remaining activities were 77%, 100%, and 81% 
for BbAfcBmut, BbAfcB, and CpAfc2, respectively. For BbAfcBmut, a half-life of 66 hours was 
determined, whereas it was 82 hours for CpAfc2.  
In addition to LNFP II, small amounts of LNFP V (i.e. the LNFP isomer where Fuc is α1,3-linked 
to the reducing end Glc moiety of LNT) were detected in the reaction with 3FL and LNT catalysed by 
BbAfcBmut (Figure A.6). After 3 hours of reaction, the yield of LNFP V was 5% at A:D 10 and 0.6% at 
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A:D 1 corresponding to 11% and 5% of the total transfucosylation yield, respectively. No LNFP V was 
detected in the reaction catalysed by CpAfc2, and for WT BbAfcB yields never exceeded 0.5%.    
In most cases, significantly higher yields were obtained at A:D 10 compared to A:D 1 (Table 
2). To further explore the influence of A:D and substrate concentration, BbAfcB and BbAfcBmut were 
employed at A:D 1, 2, 5, and 10 combining two different donor concentrations (10 mM and 20 mM) 
with two different acceptor concentrations (20 mM and 100 mM) (Table 3; Figure 4). In this way, the 
effect of donor concentration, acceptor concentration, and their molar ratio (A:D) on product 
formation and yield were investigated simultaneously. In all cases, the same enzyme showed similar 
reaction progress over time independent of the A:D and substrate concentration employed (Figure 
4). To clearly investigate the effect of both parameters, initial transfucosylation rates were divided by 
the initial 3FL concentration (10 or 20 mM). Doing so, almost identical values were obtained for 
reactions with identical LNT acceptor concentrations (Table 3). In turn, the initial transfucosylation 
rates increased 4 times for BbAfcBmut and CpAfc2 when the acceptor concentration was increased 5 
times (Table 3). For BbAfcB this was not the case, as a 5-fold increase in acceptor concentration led 
to a 1.5-fold increase in initial transfucosylation rate only (Table 3). Similar trends were observed for 
maximum LNFP II yields obtained within 60 minutes of reaction (Table 3).  
 
Discussion 
 
Examples of loop deletions exist as a strategy for improving transglycosylation activity in microbial 
enzymes with polymeric substrates, e.g. xyloglucan endo-hydrolases (using xyloglucan endo-
transglycosylases as template) [24] and α-amylases (using cyclodextrin glucanotransferases as 
template) [25]. However, point mutations – single or multiple – in and around the active site 
comprise by far the most pursued strategy for exoglycosidases [26-29], and is also the only protein 
engineering strategy previously used on GH29 α-L-fucosidases [10, 11, 22, 30]. However, for a 
sialidase from Trypanosoma rangeli it was shown that exchanging a loop of seven amino acids 
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approx. 10 Å from the active site with the seven amino acids found in the corresponding loop in the 
native transsialidase from Trypanosoma cruzi significantly improved transsialylation yields [14]. The 
loop mutation mainly reduced the hydrolytic activity, whereas it had little effect on the 
transsialylation rate [29]. On a more general level, the interest in the flexible loop regions and their 
impact on enzyme function is increasing and as a consequence engineering of loop regions is 
becoming a more commonly pursued strategy [31].  
Enzymes of the GH29 family have a (β/α)8 or TIM-barrel-like fold (although one α-helix may 
be missing), where all the conserved active site residues are on the catalytic βα-loops, i.e. the loops 
that follow after the β-strands [32, 33]. The active sites of GH29 members exhibit a pocket topology 
which is common for exoglycosidases [34]. Conservation is strict among the ligand interacting 
residues inside the active site pocket, but there is large diversity in the overall shape due to variation 
in the loops surrounding the active site [32]. Crystal structures provided evidence that some of the 
loops undergo conformational changes upon substrate binding and that at least two of the loops 
take part in the catalytic process in BiAfcB (Table A.3) [22]. Thus, the loops near the active site could 
indeed be an interesting target for α-L-fucosidase engineering. The loop targeted in the current work 
appears highly flexible as it was disordered and not properly crystallized in the crystal structure of 
BiAfcB (Table A.3) [22]. In the (β/α)8-barrel structure, mutations in the catalytic βα front loops often 
do not cause stability issues since they are separated in space by the central barrel structure from 
the αβ back loops, which confer stability [33, 35]. This separation could give functional versatility in 
enzymes with (β/α)8-barrel-like folds, and the (β/α)8-barrel is therefore considered an ideal scaffold 
for rational design of novel enzyme activities [33, 35, 36]. Indeed, several reports exist on loop 
grafting, i.e. replacing βα-loops from one enzyme of the (β/α)8-barrel fold class with those from 
another, for transferring substrate specificity and function although not yet for transglycosylation 
purposes [36, 37].  
The loop mutation in the T. rangeli sialidase introduced a change in net charge of +3 and it 
was hypothesized that it altered the water network in the active site [14]. In the current work, a 23-
AC
CE
PT
ED
 M
AN
US
CR
IPT
amino acid α-helical loop with a net charge of 0 was replaced by a 17-amino acid α-helical loop with a 
net charge of -1. Rather than altering the water network it was hypothesized that this would lead to 
better shielding of the active site pocket from the surrounding aqueous environment, thus reducing 
the competing hydrolytic activity. A closed active site topology, a hydrophobic entrance to the active 
site, or obstruction of catalytic water channels to exclude water from the active site have all been 
shown to have positive effects on transglycosylation for GH33 sialidases, GH1 β-glucosidases, and 
GH13 neopullulanase [38-42]. Indeed, the study of the homology models of CpAfc2 and BbAfcB 
suggested that the α-helical loop in CpAfc2 could have a more shielding effect than the more open 
and disordered loop found in BbAfcB, although the models indicate that there is still ample room for 
water molecules in the active site (Figure 2; Figure A.4). While these were indeed models – and the 
corresponding loop in BiAfcB so flexible that it could not be crystallized [22] – the results emphasize 
that the exchange of the loop in BbAfcB with that of CpAfc2 did indeed have a major effect on the 
transfucosylation performance of BbAfcB, mainly by almost completely abolishing its hydrolytic 
activity while maintaining an initial transfucosylation rate which was approx. one order of magnitude 
lower than those observed in WT BbAfcB and CpAfc2 (Table 1; Table 2; Table 3). A drop in activity 
rate is often observed in glycosidases engineered for improved transglycosylation, especially when 
mutations are in the negative subsite (i.e. the donor binding site) and/or when more than one amino 
acid is substituted [27, 28]. Exchange of a loop in the T. rangeli sialidase with the corresponding one 
of T. cruzi transsialidase also reduced the hydrolytic activity significantly, indicating that this strategy 
– which is similar to the one employed here – particularly targets the undesirable hydrolytic activity 
[14, 29]. The loop mutation did not influence the expression levels of recombinant BbAfcB and 
BbAfcBmut in E. coli, which were similar. Enzyme stability at extended reaction times was slightly 
influenced by the loop mutation: whereas BbAfcB retained full activity after 24 hours of incubation at 
40°C, the remaining activity of BbAfcBmut was 77% and thus more similar to that of CpAfc2, which was 
81%. However, 77% is an appreciable remaining activity and it should be feasible to run the reaction 
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past 24 hours in order to obtain higher transfucosylation yields with BbAfcBmut at A:D 1. At A:D 10, 
maximum yields were obtained within 24 hours of reaction (Table 2).  
For glycosidase-catalyzed transglycosylation, product maxima are often transient due to 
hydrolysis [8]. Interestingly, despite having the highest initial transfucosylation rate, BbAfcB gave the 
lowest transfucosylation product yields. From this, it is evident that transfucosylation rate is not the 
only important factor. Indeed, when employing glycosidases for transglycosylation, hydrolytic rates 
on substrate as well as on product are just as important as the transglycosylation rate in determining 
the maximum transglycosylation yield (Table 2; Figure 3). The fact that maximum product levels were 
obtained at the shortest measured reaction time with BbAfcB (Figure 3) is indeed linked to the fact 
that this enzyme had significantly higher hydrolytic activity than BbAfcBmut and CpAfc2 (Table 1). For 
CpAfc2 the transient maximum occurred at a later stage (30 min; Figure 3), whereas the product 
hydrolysis was limited for BbAfcBmut, which had very low hydrolytic activity on 3FL compared to the 
two WT enzymes (Figure 3; Table 1). As discussed above, the transfucosylation activity was also 
approx. one order of magnitude lower, but due to the dramatic decrease in product hydrolysis, 
appreciable levels of LNFP II and LNFP III were reached with BbAfcBmut (Table 2). While CpAfc2 
produced even higher yields at A:D 10, the yields were similar with CpAfc2 and BbAfcBmut at A:D 1 
(Table 2).   
 It is well established that both substrate concentration and A:D affect transglycosylation 
rates and yields [8]. The transfucosylation data on LNT with 3FL as donor catalyzed by BbAfcB or 
BbAfcBmut suggested that the progress and mechanism of the reactions were independent of A:D and 
substrate concentration (Figure 4). Dividing initial transfucosylation rates and transfucosylation yields 
by the initial donor substrate concentration revealed similar values for reactions with identical 
acceptor concentrations, indicating that the effect of donor substrate concentration was linear in this 
range (Table 3). Analogously, there was a clear effect of the acceptor concentration: For BbAfcBmut a 
4-fold higher initial rate and a 5.5-fold higher yield was obtained when the acceptor concentration 
was increased 5 times (Table 3). A similar trend was observed for CpAfc2, although the increase in 
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yield was only 3-fold (Table 3). For WT BbAfcB, increases in rate and yield were only 1.5-fold (Table 
3). Most likely, initial transfucosylation rates were heavily influenced by the large hydrolytic activity 
of this enzyme, and the effect of A:D was therefore not as evident (Table 1; Table 3). Indeed, the 
transient maximum was passed within the first two minutes of reaction, and the initial 
transfucosylation rate and maximum yield may therefore be higher than established here (Figure 4).  
 The transfucosylation activity was tested on two different HMO acceptor substrates of equal 
size, namely LNT and LNnT which differ only in the linkage between the non-reducing Gal moiety and 
GlcNAc (β1,3 in LNT and β1,4 in LNnT; Figure 1). Both were used as substrates for transfucosylation 
with 3FL, resulting in formation of HMO pentaose structures LNFP II and LNFP III, respectively, as 
identified by LC-ESI-MS/MS (Figure 1). However, for WT α-1,3/4-L-fucosidases BbAfcB and CpAfc2 
initial transfucosylation rates were 4-5 times higher on LNT compared to LNnT (Table 2). For 
BbAfcBmut the difference was more moderate, the initial rate being only 2 times higher for LNT (Table 
2). Similarly, maximum yields were higher for LNFP II than for LNFP III, the difference between the 
enzymes being less distinct (Table 2). The slightly larger preference for LNnT observed in BbAfcBmut 
compared to the WT α-1,3/4-L-fucosidases could be linked to the less strict regioselectivity observed 
for the engineered enzyme in the transfucosylation of LNT, where formation of minor amounts of 
LNFP V was observed. Although the crystal structure of orthologue BiAfcB indicates that the reducing 
end of LNFP II protrudes from the enzyme, while the non-reducing end Gal moiety is buried in the 
active site pocket (Figure 2; Figure A.1) [22], the formation of LNFP V indicates that BbAfcBmut must 
be able to accommodate LNT in a reverse manner. This may be a result of the loop engineering since 
only negligible amounts of LNFP V were observed in reactions catalyzed by WT BbAfcB. However, no 
LNFP V was observed in reactions catalysed by CpAfc2, indicating that it was not the loop as such, but 
rather its effect on BbAfcBmut. LNFP V is present in human milk, albeit only in very small amounts 
[43].  
 The only previously reported engineering of BbAfcB is its transformation into an α-L-
fucosynthase, giving an LNFP II yield of 41% when using 34 times more enzyme than in the current 
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work [22]. While this strategy is appealing due to its simple, generic nature, especially α-
glycosynthases struggle with low donor substrate stability [22, 44]. GH29B α-1,3/4-L-fucosidases are 
particularly appealing in terms of engineering for improved transfucosylation activity – and for use in 
transfucosylation in general – since they appear to maintain their high regioselectivity in the 
transfucosylation reaction, while the GH29A α-L-fucosidases often do not [10, 12, 22]. So far, the only 
other example of engineering of a GH29B α-1,3/4-L-fucosidase is the extensive work on BiAfcB [10, 
11]. Together with these results, the current work emphasizes the potential of protein engineering 
for improved transfucosylation performance among GH29B enzymes, as well as for targeted loop 
engineering in general. In addition, the work highlights how the competition between 
transglycosylation and hydrolysis rates governs glycosidase-catalysed transglycosylation and why 
reduction of hydrolytic activity is an important strategy in transglycosidase engineering.  
The use of glycosidase-catalysed transglycosylation represents one strategy for in vitro 
production of HMOs [7, 8]. An alternative strategy for in vitro HMO production is the use of 
prokaryotic fucosyltransferases; however, their expression is challenging and their use requires a 
multi-enzyme setup for regeneration of the required expensive substrate GDP-L-fucose [9]. For fairly 
simple HMO structures, fermentation of engineered Escherichia coli appears to be a viable strategy. 
For instance, HMOs including 2’-fucosyllactose (2’FL), 3FL, LNT, and LNnT have been produced by 
engineered E. coli with yields generally around 10 g/L [7, 45-47]. However, for more complex 
structures such as LNFPs yields are generally much lower and only LNFP I and LNFP III have been 
reported as fermentation products with yields below 1 g/L [48, 49]. A process combining 
fermentation products with regioselective enzymatic transfucosylation catalysed by α-L-fucosidases 
could lead to a mixture of 3FL and LNT enriched with LNFP II, which is the seventh most abundant 
HMO in general and the second most abundant HMO in non-secretor milk [6].  
Being of lactic acid bacterial origin, the use of engineered BbAfcB for production of human 
milk oligosaccharides may be a more suitable strategy than employing CpAfc2 from pathogenic C. 
perfringens. The newly obtained transfucosylation activity could be exploited to expand the 
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complexity of HMO production: mixtures of 3FL and LNT – e.g. of fermentation origin – could be 
enriched with LNFP II, while mixtures of 3FL and LNnT could be enriched with LNFP III. 
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Figure legends 
 
Figure 1. Transfucosylation reactions catalysed by α-L-1,3/4-fucosidases. Top: Formation of lacto-N-
fucopentaose II (LNFP II) from 3-fucosyllactose (3FL) and lacto-N-tetraose (LNT). Bottom: Formation 
of LNFP III from 3FL and lacto-N-neotetraose (LNnT). The fucosyl moieties are shown in blue.  
 
Figure 2. Homology model of BbAfcB (white) indicating the catalytic residues D703 and E746 (yellow). 
The ligand comprising Fuc (orange), GlcNAc, and non-reducing end Gal (purple-blue) moieties from 
LNFP II is from the crystal structure of BiAfcB (PDB: 3UET). The BbAfcB α-helical loop (759-
AAYNDGVDKVSLKPGQMAPDGKL-781) subjected to mutation in the current work is shown in black. 
The position and shape of corresponding α-helical loop (259-DIEKMKERENPTYLNNG-275) in the 
CpAfc2 homology model to which it was changed is indicated in pink.  
 
Figure 3. Transfucosylation catalysed by the α-L-1,3/4-fucosidases. Molar transfucosylation yields 
([LNFP II/III]/[3FL]0) obtained in transfucosylation catalysed by BbAfcBmut (squares), BbAfcB 
(triangles), and CpAfc2 (circles) using 3FL as fucosyl donor substrate and either LNT (left) or LNnT 
(right) as acceptor substrate (n = 2). Acceptor-to-donor ratios (A:D) were either 10 (10 mM 3FL and 
100 mM LNT/LNnT; filled symbols) or 1 (20 mM of both substrates; open symbols).  
 
Figure 4. Effect of acceptor-to-donor ratio (A:D) and substrate concentration on transfucosylation. 
The reaction was catalysed by BbAfcBmut (squares) and BbAfcB (triangles) for up to 60 min using 3FL 
and LNT (n = 2). For A:D 1 and 5 (dashed lines) the 3FL donor concentration was 20 mM, whereas it 
was 10 mM for A:D 2 and 10 (solid lines). For A:D 1 and 2 (open symbols) the LNT acceptor 
concentration was 20 mM, whereas it was 100 mM for A:D 5 and 10 (filled symbols). 
Transfucosylation activity is given as molar LNFP II yield on donor (%; left) and as LNFP II 
concentration (mM; right).  
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Figure 4.  
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Tables 
Table 1. Hydrolytic activity of α-1,3/4-L-fucosidases on 3FL (n = 2).  
Enzyme Hydrolytic activity on 3FL 
(μmol min-1 (μmol enzyme)-1) 
CpAfc2 18 ± 3b 
BbAfcB 59 ± 1.5a  
BbAfcBmut 0.01 ± 0.001c 
a-cSignificant difference (p < 0.05) between enzymes. 
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Table 2. Initial transfucosylation rate, maximum conversion yield ([LNFP II/III]/[3FL]0), and yield after 
24 hours in transfucosylation catalysed by BbAfcB, BbAfcBmut, and CpAfc2 using 3FL as donor 
substrate and either LNT or LNnT as acceptor substrate (n = 2) at acceptor-to-donor ratios (A:D) of 
either 10 or 1.  
Acceptor Enzyme  A:D 3FL 
(mM) 
Initial transfucosylation 
rate (μM min-1) 
Maximum yield of 
LNFP II/III (% (mM)) 
LNFP II/III yield 
after 24 hours (%) 
LNT BbAfcBmut 10 10 46 ± 6d,x 39 ± 2b,x (3.9) 34 ± 11 
  1 20 24 ± 4d,y 13 ± 4c,y (2.7) 13 ± 4 
 BbAfcB 10 10 709 ± 17ab,x 14 ± 0.3c,x (1.4) 0.7 ± 0.04* 
  1 20 870 ± 237a,x 8.7 ± 2c,y (1.7) 0.4 ± 0.1* 
 CpAfc2 10 10 517 ± 56bc,x 50 ± 8a,x (5.0) 0.8 ± 0.8* 
  1 20 273 ± 0.3cd,y 16 ± 3c,y (3.2) 0.4 ± 0.6* 
LNnT BbAfcBmut 10 10 23 ± 2c,y 11 ± 0.3b,y (1.1) 5.4 ± 2* 
  1 20 12 ± 2c,z 8.1bc,y (1.6) 8.1 
 BbAfcB 10 10 163 ± 16a,y 3.3 ± 0.3d,z (0.3) 0.1 ± 0.02* 
  1 20 169 ± 22a,y 1.7 ± 0.2d,z (0.3) 0* 
 CpAfc2 10 10 101 ± 5b,z 17 ± 3a,y (1.7) 0.1 ± 0.03* 
  1 20 77 ± 6b,z 6.2 ± 0.2c,y (1.2) 0.04 ± 0.002* 
a-dSignificant difference (p < 0.05) between values for each parameter comparing enzymes on the same 
acceptor substrate (LNT or LNnT) at both A:Ds. x-zSignificant difference (p < 0.05) between values for each 
parameter comparing acceptor substrates for the same enzyme at both A:Ds. *For yields after 24 hours, an 
asterisk indicates whether this value is significantly different from the maximum yield, i.e. if significant product 
hydrolysis took place within 24 hours.  
 
Table 3. Effect of acceptor-to-donor ratio (A:D) and substrate concentrations on initial 
transfucosylation rate (divided by [3FL]0 to clearly observe the effect of varying donor and acceptor 
concentrations) and on maximum LNFP II yield (given as molar yield on donor, i.e. [LNFP II]/[3FL]0) 
obtained within 60 min in the transfucosylation catalysed by BbAfcB, BbAfcBmut, and CpAfc2 using 3FL 
and LNT (n = 2).  
A:D 3FL 
(mM) 
LNT  
(mM) 
Initial transfucosylation rate  
(μM min-1 (mM 3FL0)-1) 
Maximum LNFP II yield in 60 min 
(mM (mM 3FL0)-1) 
   BbAfcBmut BbAfcB  CpAfc2 BbAfcBmut BbAfcB  CpAfc2 
1 20 20 1.2 ± 0.2d 44 ± 12b 14 ± 0.0c 0.05 ± 0.004e 0.09 ± 0.02de 0.17 ± 0.03c  
2 10 20 1.2 ± 0.1d 51 ± 0.4b - 0.05 ± 0.01e 0.10 ± 0.001d - 
5 20 100 4.8 ± 0.2cd 70 ± 5.3a - 0.28 ± 0.01b 0.16 ± 0.02c - 
10 10 100 4.6 ± 0.6cd 71 ± 1.7a 52 ± 5.6b 0.25 ± 0.004b 0.15 ± 0.001cd 0.51 ± 0.07a 
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a-dSignificant difference (p < 0.05) between values for each parameter.  
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